These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 15872032)

  • 1. Rate-control vs. rhythm-control in patients with atrial fibrillation: a meta-analysis.
    Testa L; Biondi-Zoccai GG; Dello Russo A; Bellocci F; Andreotti F; Crea F
    Eur Heart J; 2005 Oct; 26(19):2000-6. PubMed ID: 15872032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis.
    de Denus S; Sanoski CA; Carlsson J; Opolski G; Spinler SA
    Arch Intern Med; 2005 Feb; 165(3):258-62. PubMed ID: 15710787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    DiMarco JP; Flaker G; Waldo AL; Corley SD; Greene HL; Safford RE; Rosenfeld LE; Mitrani G; Nemeth M;
    Am Heart J; 2005 Apr; 149(4):650-6. PubMed ID: 15990748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verapamil versus digoxin and acute versus routine serial cardioversion for the improvement of rhythm control for persistent atrial fibrillation.
    Hemels ME; Van Noord T; Crijns HJ; Van Veldhuisen DJ; Veeger NJ; Bosker HA; Wiesfeld AC; Van den Berg MP; Ranchor AV; Van Gelder IC
    J Am Coll Cardiol; 2006 Sep; 48(5):1001-9. PubMed ID: 16949494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical factors associated with abandonment of a rate-control or a rhythm-control strategy for the management of atrial fibrillation in the AFFIRM study.
    Curtis AB; Seals AA; Safford RE; Slater W; Tullo NG; Vidaillet H; Wilber DJ; Slee A
    Am Heart J; 2005 Feb; 149(2):304-8. PubMed ID: 15846269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation: rhythm control offers no advantage over rate control for some, but not all.
    Li YB; Hu CL; Liu J; Chen YX; Qu Z; Xu JL; Chen JB; Wan J; Tang QZ; Huang CX
    Med Hypotheses; 2007; 69(1):206-8. PubMed ID: 17011138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis.
    Burgess DC; Kilborn MJ; Keech AC
    Eur Heart J; 2006 Dec; 27(23):2846-57. PubMed ID: 17015402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mortality after catheter ablation for atrial fibrillation compared with antiarrhythmic drug therapy. A meta-analysis of randomized trials.
    Dagres N; Varounis C; Flevari P; Piorkowski C; Bode K; Rallidis LS; Tsougos E; Leftheriotis D; Sommer P; Hindricks G; Kremastinos DT
    Am Heart J; 2009 Jul; 158(1):15-20. PubMed ID: 19540387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mending the rhythm does not improve prognosis in patients with persistent atrial fibrillation: a subanalysis of the RACE study.
    Rienstra M; Van Gelder IC; Hagens VE; Veeger NJ; Van Veldhuisen DJ; Crijns HJ
    Eur Heart J; 2006 Feb; 27(3):357-64. PubMed ID: 16275661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rate control versus rhythm control.
    Vidaillet H; Greenlee RT
    Curr Opin Cardiol; 2005 Jan; 20(1):15-20. PubMed ID: 15596954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical factors that influence response to treatment strategies in atrial fibrillation: the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Curtis AB; Gersh BJ; Corley SD; DiMarco JP; Domanski MJ; Geller N; Greene HL; Kellen JC; Mickel M; Nelson JD; Rosenberg Y; Schron E; Shemanski L; Waldo AL; Wyse DG;
    Am Heart J; 2005 Apr; 149(4):645-9. PubMed ID: 15990747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.
    Chung MK; Shemanski L; Sherman DG; Greene HL; Hogan DB; Kellen JC; Kim SG; Martin LW; Rosenberg Y; Wyse DG;
    J Am Coll Cardiol; 2005 Nov; 46(10):1891-9. PubMed ID: 16286177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial.
    Klein AL; Grimm RA; Jasper SE; Murray RD; Apperson-Hansen C; Lieber EA; Black IW; Davidoff R; Erbel R; Halperin JL; Orsinelli DA; Porter TR; Stoddard MF;
    Am Heart J; 2006 Feb; 151(2):380-9. PubMed ID: 16442904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The clinical challenge of the atrial fibrillation].
    de Berrazueta Fernández JR
    An R Acad Nac Med (Madr); 2007; 124(2):361-78. PubMed ID: 18069601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
    Flaker GC; Belew K; Beckman K; Vidaillet H; Kron J; Safford R; Mickel M; Barrell P;
    Am Heart J; 2005 Apr; 149(4):657-63. PubMed ID: 15990749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Occurrence and characteristics of stroke events in the Atrial Fibrillation Follow-up Investigation of Sinus Rhythm Management (AFFIRM) study.
    Sherman DG; Kim SG; Boop BS; Corley SD; Dimarco JP; Hart RG; Haywood LJ; Hoyte K; Kaufman ES; Kim MH; Nasco E; Waldo AL;
    Arch Intern Med; 2005 May; 165(10):1185-91. PubMed ID: 15911734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital.
    Allen Lapointe NM; Sun JL; Kaplan S; d'Almada P; Al-Khatib SM
    Am J Cardiol; 2008 Apr; 101(8):1134-41. PubMed ID: 18394447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation.
    Nieuwlaat R; Olsson SB; Lip GY; Camm AJ; Breithardt G; Capucci A; Meeder JG; Prins MH; Lévy S; Crijns HJ;
    Am Heart J; 2007 Jun; 153(6):1006-12. PubMed ID: 17540203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter.
    Connolly SJ; Crijns HJ; Torp-Pedersen C; van Eickels M; Gaudin C; Page RL; Hohnloser SH;
    Circulation; 2009 Sep; 120(13):1174-80. PubMed ID: 19752319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrial fibrillation: goals of therapy and management strategies to achieve the goals.
    Padanilam BJ; Prystowsky EN
    Med Clin North Am; 2008 Jan; 92(1):217-35, xii-xiii. PubMed ID: 18061006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.